Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valter Gattei

Showing results (181-190 of 190) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 190 results.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2020
<i>IGLV3-21</i> is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signalingPalash C Maity, Mayas Bilal, Marvyn T Koning, et al.
Hemasphere|February 18, 2026
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformationChiara Cosentino, Samir Mouhssine, Antonella Zucchetto, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
The Lancet. Haematology|June 27, 2024
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trialAlessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, et al.
Nature Communications|October 20, 2022
Proteogenomics refines the molecular classification of chronic lymphocytic leukemiaSophie A Herbst, Mattias Vesterlund, Alexander J Helmboldt, et al.
Blood|May 13, 2025
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNAMaria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, et al.
Blood Advances|January 18, 2025
Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levelsRiccardo Moia, Donatella Talotta, Lodovico Terzi Di Bergamo, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
Hematological Oncology|December 29, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World StudyErnesto Vigna, Enrica Antonia Martino, Annalisa Pitino, et al.
Blood Advances|January 7, 2026
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian CohortEnrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, et al.
Pageof 19

Showing results (181-190 of 190) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 190 results.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2020
<i>IGLV3-21</i> is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signalingPalash C Maity, Mayas Bilal, Marvyn T Koning, et al.
Hemasphere|February 18, 2026
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformationChiara Cosentino, Samir Mouhssine, Antonella Zucchetto, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
The Lancet. Haematology|June 27, 2024
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trialAlessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, et al.
Nature Communications|October 20, 2022
Proteogenomics refines the molecular classification of chronic lymphocytic leukemiaSophie A Herbst, Mattias Vesterlund, Alexander J Helmboldt, et al.
Blood|May 13, 2025
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNAMaria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, et al.
Blood Advances|January 18, 2025
Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levelsRiccardo Moia, Donatella Talotta, Lodovico Terzi Di Bergamo, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
Hematological Oncology|December 29, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World StudyErnesto Vigna, Enrica Antonia Martino, Annalisa Pitino, et al.
Blood Advances|January 7, 2026
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian CohortEnrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, et al.
Pageof 19